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Abstract
Background: This double-blind, randomized, controlled trial investigated the effect of the
phosphodiesterase-5 inhibitor tadalafil on the microcirculation in patients with cold Complex
Regional Pain Syndrome (CRPS) in one lower extremity.
Methods: Twenty-four patients received 20 mg tadalafil or placebo daily for 12 weeks. The
patients also participated in a physical therapy program. The primary outcome measure was
temperature difference between the CRPS side and the contralateral side, determined by
measuring the skin temperature with videothermography. Secondary outcomes were: pain
measured on a Visual Analogue Scale, muscle force measured with a MicroFet 2 dynamometer, and
level of activity measured with an Activity Monitor (AM) and walking tests.
Results: At the end of the study period, the temperature asymmetry was not significantly reduced
in the tadalafil group compared with the placebo group, but there was a significant and clinically
relevant reduction of pain in the tadalafil group. Muscle force improved in both treatment groups
and the AM revealed small, non-significant improvements in time spent standing, walking, and the
number of short walking periods.
Conclusion: Tadalafil may be a promising new treatment for patients that have chronic cold CRPS
due to endothelial dysfunction, and deserves further investigation.
Trial Registration: The registration number in the Dutch Trial Register is ISRCTN60226869.
Background
Complex regional pain syndrome (CRPS) is a painful dis-
order that typically occurs as a complication of surgery or
trauma. There are two types of CRPS: in type 1 no overt
nerve lesion is detectable, and in type II a nerve lesion is
present [1,2]. Diagnosis is based mainly on consensus-
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only patients with CRPS type 1. The main characteristics
of CRPS are continuous pain, sensory disturbances,
marked changes in tissue blood flow and skin surface tem-
perature, edema, sweating, movement disorders, and
trophic changes of the skin. The severity of the symptoms
is often disproportional to the initial event [5,6].
During the chronic stage of the disease, inflammatory
signs give way to atrophy, reduced regional blood flow,
and consequently, reduced skin temperature [7,8].
Impaired microcirculation causes vasoconstriction [9], tis-
sue hypoxia [8], and metabolic tissue acidosis [10,11] that
in turn affect the nutritive blood flow in superficial and
deep tissues [6,12]. A histopathologic study of skin sam-
ples in chronic CRPS showed 'numerous abnormal
changes in vascular innervation and structure' [13]. The
microcirculation is regulated by neural and endothelial
factors [14].
The regulatory neural factors were examined by Wasner et
al., who induced whole-body temperature changes to
study the cutaneous sympathetic vasoconstrictor activity
in CRPS. They identified three vascular regulation pat-
terns: the 'warm', the 'intermediate', and the 'cold', distin-
guished by skin temperature and by the difference in
perfusion values between the affected and contralateral
limbs [15]. This asymmetry in blood flow and tempera-
ture was dynamic and most prominent at a medium to
high level of vasoconstrictor activity. It was suggested that
in CRPS, unilateral inhibition of sympathetic vasocon-
strictor neurons led to a warmer affected limb in the acute
stage, but secondary changes in neurovascular transmis-
sion, namely supersensitivity to circulating catecho-
lamines and the increase of alpha-1 adrenoceptors, would
lead to vaso-constriction and cold skin in the chronic
stage of the disease [15].
Schattschneider et al. investigated the abilities of acetyl-
choline and sodium nitroprusside to induce endothe-
lium-dependent and endothelium-independent
vasodilation, respectively, in patients with CRPS. They
concluded that endothelial function was impaired in
chronic cold CRPS [14].
The endothelium modulates vascular tone by releasing
endothelium-derived vasodilators including nitric oxide
(NO), prostacyclin, bradykinin, and endothelium-derived
hyperpolarizing factor. In addition, a number of bio-
chemical and physical stimuli cause the release of vaso-
constrictors, including endothelin-1 (ET-1) and angi-
otensin II [16]. Within the vascular smooth muscle cell,
NO activates a soluble guanylyl cyclase that elevates the
intracellular concentration of cyclic guanosine mono-
phosphate (cGMP). Cyclic GMP in turn activates a specific
protein kinase that phosphorylates proteins and ion chan-
nels; this results in the opening of potassium channels
and hyperpolarization of the muscle cell membrane,
sequestration of intracellular calcium by the endoplasmic
reticulum, and blocking of calcium influx by the inhibi-
tion of calcium channels. The consequence is a drop in
cytosolic calcium concentrations and relaxation of the
smooth muscle that causes vasodilation [17].
Cyclic GMP is hydrolyzed to GMP by phosphodiesterase
type 5 (PDE-5). The inhibition of PDE-5 leads to an
increase in the intracellular cGMP concentration. The
PDE-5-inhibitor, tadalafil is an effective treatment for
erectile dysfunction (ED) [17], and has also been
described in the flow-mediated dilation of the brachial
artery [18], the nail fold capillary bed of patients with ED
[19], and in pulmonary arterial hypertension [20].
The aim of this double-blind, placebo-controlled, rand-
omized clinical trial was to determine whether the PDE-5
inhibitor, tadalafil could improve regional blood flow in
the involved extremity of patients with cold type CRPS,
and whether this would reduce pain and improve func-
tion.
Methods
Study subjects, design, and protocol
This double-blind, randomized, placebo-controlled study
included 24 patients with cold CRPS. Patient inclusion
took place from June 2005 to June 2007 and the data set
was completed in September 2007. Potential patients
were selected from outpatients of Erasmus Medical Center
(MC), from patients that responded to announcements in
the Dutch CRPS Patients Association magazine and web-
site, and from patients referred by anesthesiologists at
neighboring hospitals. Eligible candidates were invited to
visit our outpatient clinic and the pain clinicians FW,
FJPMH, and MVM selected patients with stable cold CRPS
according to the criteria described by Harden and Bruehl
[3]. Additional inclusion criteria were: age between 18
and 60 years old and CRPS limited to one lower extremity.
Patients had to be able to stand on the affected leg and
walk at least a few steps. Patients with cardiovascular or
neurovascular diseases and patients that were hypersensi-
tive to nitrates were excluded.
The sample size calculation was based on the use of the
MANOVA repeated measures design on the primary out-
come measure temperature difference. An effect size of 0.6
was used, an α of 0.05, and a power of 0.8 (1-β). The total
sample size computed by this method was 24 (12 in each
group).
Randomization was performed by the Erasmus MC phar-
macy according to the research policy of the Erasmus MC,Page 2 of 10
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researchers, and physicians were blind to the intervention
administered; only the pharmacist had the allocation
code.
Patients were randomized (12 per group) to receive either
tadalafil or a placebo over a 12-week period. Patients in
the tadalafil group started with 10 mg daily during 4
weeks and then took 20 mg daily for another 8 weeks. This
titration schedule was advised in order to avoid tolerance
effects. Patients in the placebo group also followed this
schedule of titration. Because, in the Netherlands, the use
of Tadalafil has not yet been approved for CRPS, the study
medication was stopped after the study period and the
patients were seen by FJPMH to discuss further conven-
tional treatment. All patients participated in a modified
version of the physiotherapy program described by Kem-
ler et al. [20], which is based on a graded activity approach
intended to improve function, strength, and mobility of
the affected extremity. The patients performed daily exer-
cises at home, which was instructed and supervised by a
local physiotherapist during one therapy session per
week. The therapists received written instructions, filled in
compliance reports and received feedback by telephone
and email by the first author.
Outcome measures
To determine the effects of tadalafil on the microcircula-
tion, the primary outcome measure was the temperature
difference between the CRPS affected and the contralat-
eral limbs. The secondary outcome measures were pain,
muscle force, and activity. Outcome measures were
assessed at the start and end of the study.
Temperature was measured using video thermography. In
chronic cold CRPS, a reduction in local skin temperature
is directly related to diminished tissue blood distribution
[21]. Video thermography was shown to be an effective
method for monitoring near-surface blood flow in the
limbs [22,23]. The skin temperatures of both feet were
registered with a computer-assisted infrared thermograph
(ThermaCAM SC2000, Flir Systems, Berchem, Belgium)
following a standard protocol [24]. To compare thermo-
graphic images of the feet, the means and difference in
temperature (°C) were calculated as described previously
[22]. Under normal conditions, the thermal asymmetry
between opposite sides of the body is very small; in
healthy subjects, the degree of thermal asymmetry was
less than 1% (< 0.25°C) when measured with computer-
ized thermography [22,25,26].
Pain is often described as the most prominent feature of
CRPS [27]. The patients were instructed to record daily
pain intensity, concurrent medication, and adverse events
in a diary. The pain intensity was rated according to a Vis-
ual Analogue Scale (VAS) scale (0–100 mm). The actual
pain score was recorded three times daily (0800, 1200 and
2000 h) during the week before the first and last hospital
visits; the average scores for each of those weeks were used
in the analyses.
Function was evaluated with muscle force tests, walking
capacity tests, and measurements of performance. Muscle
force of the flexors and extensors of the knee and foot was
measured using a MicroFet 2 dynamometer (Hoggan
Health Industries Inc, West Jordan, UT, USA) as described
by Bohannon and Andrews [28-30], using the 'break'
method [28]. The mean value of three measurements was
calculated and given in units of Newtons (N).
A ten meter walking test and a two minute walking test
were performed to determine the walking ability [31-33].
The first test was performed three times, at both comfort-
able and maximum walking speeds, and timed with a
stopwatch. The two minute walking test measured the
non-stop walking distance in meters.
To determine possible differences between perceived and
actual changes in activity levels, patients wore an Activity
Monitor (AM) and answered a questionnaire. The AM was
used to measure actually performed physical activity
[34,35]. The device is based on ambulatory accelerometry
and enables objective determination of activity in differ-
ent postures (lying, sitting and standing) and motions
(walking and general movement) during everyday func-
tions. It is increasingly used in research involving a variety
of patient groups, including acute [36] and chronic
[37,38] CRPS patients. The signal analysis and output
were described previously [34,35,39].
After all other measurements were completed, the AM was
fitted on each patient to measure activity over a 24-h
period in the hospital at the start and the end of the study.
The patients were instructed to continue their normal eve-
ryday activities while wearing the AM with the exception
of swimming, bathing, or showering. The following AM
outcome measures were calculated: the percentage of time
spent standing, walking, or in an upright position, and the
number of short walking periods (< 10 s). In these meas-
ures a higher value represented better performance.
Perceived activity limitations were measured with a ques-
tionnaire developed by the Dutch Measuring Mobility
Study Group that consisted of 35 questions [40]. In the
questionnaire a lower value represented better perform-
ance.
Blood pressure and pulse frequency were also recorded at
every visit.Page 3 of 10
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Differences in patient characteristics between the treat-
ment groups were analyzed with the Mann-Whitney U
test, Fisher's Exact test, and the chi square test, as appro-
priate.
A multivariate repeated-measures design was used to ana-
lyze differences in mean parameters between the treat-
ment groups, and over time (between the starting and
ending values), with group (tadalafil or placebo) and time
(start and end) as independent variables. In addition, we
analyzed the interaction between treatment and time. This
method of analysis was used despite the skewed distribu-
tion of the outcome measures, due to the robustness of
the analysis of variance [41]. Alpha was set to the conven-
tional level of 0.05. Analyses were performed with the Sta-
tistical Package for the Social Sciences, version 14.02
(SPSS Inc., Chicago, IL, U.S.A).
Statement of compliance with ethical regulations
The Medical Ethics Committee of the Erasmus MC
approved the study protocol (MEC 2004-159). The
research was performed in accordance with the Declara-
tion of Helsinki (2000) of the World Medical Association,
and written informed consent was obtained from all par-
ticipants.
The registration number in the Dutch Trial Register is
ISRCTN60226869.
Results
As the flowchart in figure 1 shows, twenty-four patients
participated and completed the study. The baseline char-
acteristics of the patients assigned to the tadalafil and pla-
cebo groups are shown in Table 1. There were no
significant differences in age, gender, duration of disease,
or smoking habit between the two experimental groups.
The results of the videothermographic measurements are
given in Table 2. Although the temperature difference
appeared to be reduced in the tadalafil group and
increased in the placebo group, the probability value was
only 0.37; thus we cannot exclude that these effects were
due to sampling error. However, there was a significant
reduction in pain intensity after tadalafil treatment, as
indicated by a 15% reduction of the VAS (from 61.3 to
52.3) in the tadalafil group. In contrast, the pain intensity
in the placebo group remained unchanged. Since the out-
come data were only assessed at the start and end of the
study, we cannot provide information on the time course
of these changes. We do know, however, from the remarks
of the patients, that most changes in temperature and pain
appeared to take place after 4 weeks, after the medication
had been doubled from 10 to 20 mg daily.
Table 3 shows the difference in muscle strength between
the contralateral and CRPS affected sides. We observed
significant improvement over time in both groups for
knee extension, but we failed to find significant differ-
ences between treatment groups.
Table 4 shows the outcome measures for the actually per-
formed activity. The results of the Activity Monitor indi-
cated that the intervention did not significantly affect
patient activity levels. This result was corroborated by the
lack of changes detected in either the ten meter walking
tests or the questionnaire (Table 5). However, there was a
significant change over time in both treatment groups in
the two minute walking test, though the difference
between groups was insignificant.
Systolic blood pressure was 134 (± 10) mmHg at the start
in the placebo group, and 130 (± 16) mmHg at the end of
the trial. In the tadalafil group the initial systolic blood
pressure was 142 (± 18) mmHg and at the end of the study
it was 140 (± 19) mmHg. There was no significant differ-
ence between treatment groups, and no changes were
observed in diastolic blood pressure.
Most patients in the tadalafil group reported a warmer
affected extremity, sometimes coupled with an itching
sensation. Two patients complained about painful mus-
cles in their whole body during the first few weeks of the
trial. Several patients in both groups experienced the
measurements as very tiresome, and felt exhausted after-
wards, however, there were no severe adverse events.
Discussion
Although this double-blind, randomised, placebo-con-
trolled study did not show a significant improvement in
blood flow in the extremities as observed by video ther-
mography, we found a significant and clinically relevant
reduction of pain in patients with chronic cold CRPS.
It has been repeatedly suggested that the temperature
asymmetry between extremities is an important diagnos-
tic measure for CRPS [42,43]. In this trial, we found a con-
siderable temperature asymmetry in all patients at
baseline that was reduced in the tadalafil group, and
slightly increased in the placebo group after the treatment
period. Although our analysis suggested these treatment
effects were insignificant, we recommend caution in inter-
preting these results because the study had low statistical
power as a result of the large variance and relatively low
covariance between time points. The observed statistical
power of the treatment × time factor was only 0.14 (alpha
= 0.05). In contrary to the placebo group, most patients in
the tadalafil group were very satisfied with the treatment,
claiming that the leg was much warmer under almost all
circumstances. Therefore, the treatment effects may bePage 4 of 10
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Flowchart Talafil study.
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PDE-5 inhibitors is erectile dysfunction (ED), prolonged
treatment with tadalafil has a vasodilative effect that has
also been described for other arteries [18-20]. However,
one study in patients with Raynaud's phenomenon (RP)
showed that a single dose did not improve digital blood
flow at baseline, increase the response to heating, or atten-
uate cold-induced vasoconstriction [44]. However, a
review that included several reports found that prolonged
treatment with tadalafil was associated with improved
microcirculation, symptomatic relief, and ulcer healing in
patients with secondary RP [45].
Our results are in accordance with the latter conclusions.
We observed a reduction in the temperature asymmetry
that was most likely caused by restored microcirculation.
The variation in temperature data may be an indication
that in some patients other, possibly central, thermo-reg-
ulatory mechanisms may have interfered with the periph-
eral blood flow.
Our patient population is too heavily weighted towards
women. The usual ratio is 4:1 [46,47], and we included 20
women and 4 men. Although it has been suggested, that
the influence of hormonal etiological factors may be
involved in the pathogeneses of CRPS [47], there are no
indications, that these factors still play a role in the vascu-
lar alterations in the chronic CRPS.
Pain, which is the most important parameter of CRPS, was
significantly reduced compared to placebo. However, in
pain studies a 30% increase is usually considered mean-
ingful, and 50% robust. Since we found a mere reduction
of 15%, this should be interpreted with care. Pain in CRPS
may be due to a neuropathic cause [13,48], there may be
sympathetically maintained pain [49], or it could be
caused by local ischemia [8,50], perhaps even in the same
patient. It seems likely, that the present reduction in pain
was achieved by an improvement in local ischemia, leav-
ing the other causes unchanged. On the other hand, an
increased physical activity could consequently result in an
increased awareness of pain. This needs further investiga-
tion.
We also observed a small, but insignificant improvement
in muscle force over time. This increase might have
resulted from physical therapy and the home exercise pro-
gram, or it could have been due to a learning effect after
repeated muscle force testing. In both groups we observed
a slight reduction in the asymmetry in muscle force
between the CRPS affected and contralateral sides. The
asymmetry was largest in the foot dorsal flexion. How-
ever, foot dorsal flexion was also partly influenced by the
pain arising from the pressure of the measurement device
on the plantar side of the foot; this was the most painful
area in most patients. Because these improvements were
observed in both groups, muscle force was not apparently
Table 1: Patient characteristics
tadalafil placebo P-value
n 12 12
Age, years 39.8 ± 13.1 36.5 ± 10.6 0.56 1
Gender (female/male) 9/3 11/1 0.29 2
Duration of CRPS, months 37.1 ± 24.5 55.7 ± 52.3 0.60 1
Smoking (yes/ex-smoker/no) 6/1/5 4/2/6 0.66 3
Temperature of CRPS foot, °C 26.8 ± 2.8 28.3 ± 4.7 0.60 1
Temperature of contra lateral foot, °C 28.5 ± 2.8 29.9 ± 3.3 0.27 1
Difference in temperature, °C 1.7 ± 0.77 1.7 ± 2.6 0.411
1 Mann Whitney U test; 2 Fisher's Exact test; 3 χ2
test Values are the mean ± SD unless otherwise indicated
Table 2: Temperature and Pain.
tadalafil placebo
start end start end Pt Pgt
Temperature difference (in °C) 1.71 ± 0.77 1.09 ± 1.6 1.65 ± 2.6 1.77 ± 1.9 0.54 0.37
Pain intensity VAS (0–100 mm) 61.3 ± 14.1 52.3 ± 19.1 57.0 ± 12.1 56.5 ± 10.8 0.03* 0.04*
The difference in temperature (°C) between the two feet, measured with videothermography. The Visual Analogue Scale (VAS) was used to 
measure pain intensity three times daily during the week preceding the hospital visits. The start and end times were when treatment started at t = 
0 and ended at t = 12 weeks.
Pt = P-value for differences over time; Pgt = P-value for interaction Group*TimePage 6 of 10
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group.
During the trial, most patients in the tadalafil group expe-
rienced a large improvement in walking ability. Some
reported that they were able to leave their crutches at
home when walking short distances, even outdoors. How-
ever, the results of the walking tests did not reflect this
improvement. We found only a small, non-significant
progression in the ten meter walking tests. A closer evalu-
ation revealed that some of the improved patients were
walking with two crutches at high-speed at the start of the
trial, and walked without crutches at the end of the trial,
but at the cost of a slower walking speed. Thus, the
improvement was not expressed in speed, but in quality of
walking. We found significant increases in the two minute
walking test in both treatment groups, and an indication
of improvement in the walking questionnaire. These find-
ings were supported by the results from the activity mon-
itoring. Although the improvements were insignificant,
there were small increases in standing, walking, and the
number of short walking periods.
Although we assumed we had recruited a homogeneous
study population with chronic cold CRPS, not all patients
reacted similarly to the intervention. Most patients
responded very well to tadalafil, and reported a warmer
extremity with a reduction of pain, but two patients expe-
rienced no improvement at all, and the CRPS side
remained up to 4 °C colder than the unaffected side. This
lack of responce was most likely due to the presence of
other central or peripheral factors that contributed to the
disturbed vasodynamics in chronic cold CRPS, factors that
were not influenced by cGMP stimulation through PDE-5
inhibitors. On the other hand, two patients in the placebo
group experienced an almost complete recovery from pain
and impairment. This might have been due to the effects
of physical therapy, or a combination of the effects of the
therapy and extra attention they received while perform-
ing tests as a trial participant. In either case, these
improvements indicate that a program directed at improv-
ing function may be very effective for patients with
chronic cold CRPS, even in cases that have lasted more
than four years.
This trial was limited to a period of 12 weeks. Little is
known about the effects of using PDE-5 inhibitors over a
longer period. In patients who experienced reduced pain
as a result of tadalafil, a remarkable improvement in func-
tion was observed. The use of crutches was reduced and
Table 3: Differences in muscle strength.
tadalafil placebo
start end start end Pt Pgt
Knee extension 64.2N (64.8%) 56.7N (70.3%) 97.7N (45.2%) 80.3N (58.9%) 0.01* 0.05
Knee flexion 52.0N (66.1%) 45.2N (70.7%) 70.4N (52.9%) 43.5N (71.8%) 0.12 0.08
Foot dorsal flexion 79.6N (53.6%) 84.3N (51.0%) 102.5N (39.5%) 81.4N (52.1%) 0.40 0.28
Foot plantar flexion 93.0N (56.4%) 100.2N (57.0%) 134.6N (42.4%) 76.1N (64.1%) 0.05 0.34
Results of the muscle force tests measured with the MicroFet 2 Dynamometer. Values indicate the differences in muscle strength between the 
CRPS affected and contralateral sides. All values are given in units of Newtons (percent difference between the two sides). The start and end times 
were when treatment started at t = 0 and ended at t = 12 weeks.
Pt = P-value for differences over time; Pgt = P-value for interaction Group*Time
Table 4: Activity limitations determined using the AM.
tadalafil placebo
start end start end Pt Pgt
% Time Standing 8.3 ± 2.8 10.7 ± 6.1 10.5 ± 4.3 10.3 ± 3.3 0.25 0.19
% Time Walking 4.5 ± 2.2 5.3 ± 2.8 5.6 ± 2.9 6.5 ± 3.8 0.15 0.88
% Time Upright 12.8 ± 4.5 16.0 ± 8.3 16.1 ± 7.0 16.9 ± 6.9 0.18 0.40
Number of Walking periods < 10 s 119.9 ± 50.8 138.7 ± 67.9 141.7 ± 81.8 146.4 ± 58.8 0.40 0.61
The Activity Monitor measurements were taken over a 24-h period, and are given as mean ± SD. In all these measurements a higher value indicates 
better performance. The start and end times were when treatment started at t = 0 and ended at t = 12 weeks.
Pt = P-value for differences over time; Pgt = P-value for interaction Group*TimePage 7 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2008, 9:143 http://www.biomedcentral.com/1471-2474/9/143the number of short walking periods increased. However,
the perceived improvements were small, as reported in the
walking ability questionnaire. Thus, it may take a longer
period of time for patients to acknowledge the extent of
improvements. We speculate that over time, with tadalafil
patients may acquire an activity pattern closer to normal
and improvements in function due to the reduction of
pain and the subsequent reduction in fear-avoidance,
which has been described as one of the limiting factors in
CRPS [51].
It has been suggested that CRPS is primarily a disease of
the central nervous system [52]. In any case it is a multi-
faceted disorder, and any effort to treat only one facet is
bound to result in failure [53]. However, in this trial we
have solely concentrated on the question, whether the
inhibition of PDE-5 could improve the blood flow in
CRPS. Future investigations should include a larger study
group of patients with chronic cold CRPS and an effort
should be made to select only patients with endothelial
dysfunction. A longer trial period would be required to
investigate whether the improvements last. It would also
be interesting to investigate whether this newly gained
improvement in function, supported by an activity pro-
gram if necessary, would be sufficient to sustain further
progression in activity.
Conclusion
Tadalafil may be a promising new treatment for patients
that have cold CRPS due to endothelial dysfunction. The
PDE-5 inhibitor produced a clinically relevant reduction
in the asymmetry in temperature between the affected and
unaffected feet in CRPS, most likely due to the restoration
of blood flow in the affected extremity. We also observed
a significant reduction of pain compared to placebo, likely
due to an increase in vasodilation and the abolishment of
ischemia. Future investigations should focus on the long-
term effects of tadalafil on improvements in function.
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